

# STIMULAN<sup>®</sup>

## Case study

Courtesy of Dr. Daniel Schlatterer

Orthopaedic Surgeon, Atlanta, GA, USA

### Clinical particulars

73-year-old female with osteomyelitis caused by Group B *Streptococcus* and MRSA infection. Presented with exposed hardware and post-operative drainage issues, 1 year after pilon fracture repair and subsequently 2 weeks after removal of all hardware.

### Treatment

Hardware removal and repeat debridement on the medial side of the ankle resulted in a large dead space which was managed using STIMULAN mixed with antibiotic to form a paste.

### Outcome

6 months after treatment the patient was free from infection, fully weight-bearing and without restrictions on activity – with complete absorption of STIMULAN paste.



Presentation



Post-operative



1 month



11 weeks



6 months



15 months

For indications, contraindications, warnings and precautions see Instructions for Use. Concurrent use of locally administered antibiotics may affect setting time, absorption characteristics and/or bone formation. It is the surgeon/healthcare professional's responsibility to give due consideration to the details in the medicinal product marketing authorisation in deciding whether it is appropriate for the patient under his/her care. The relevant Summary of Product Characteristics (SmPC) must be consulted. The type and dose of medicinal substance should also be assessed according to the individual patient's clinical circumstance.

This brochure may include the use of STIMULAN or techniques that go beyond the current clearance/approval granted by the relevant regulatory authority. Please contact your local representative for further information.

©2020, Biocomposites, STIMULAN, Bringing Calcium to Life, Power to Transform Outcomes and DRy26 are trademarks/registered trademarks of Biocomposites Ltd. All rights reserved. No unauthorised copying, reproduction, distributing or republication is allowed unless prior written permission is granted by the owner, Biocomposites Ltd.

Patents granted: GB2367552, EP I204599 B1, US 6780391, EP 2594231 B1, US 88883063, CN ZL201210466117.X, GB2496710, EP 3058899 B1, US I0390954  
Patents pending: GB1502655.2, US I5/040075, CN 201610089710.5, GB1704688.9, EP I8275044.8, US I5/933936, CN I08619579A